Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and admin

Change in fair value of acquisition consideration

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Twist Bioscience Corp

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. Its products include genes, oligo pools, Next Generation Sequencing (NGS), variant libraries, synthetic controls, antibody discovery, and SARS-CoV-2 Tools. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Twist Bioscience Corp meets Q1 expectations, eyes growth opportunities

Twist Bioscience Corp's Q1 performance met or exceeded expectations across key revenue segments, with a focus on expanding customer base and improving turnaround times.
While facing challenges such as COVID impact on China sales and margin dips due to fixed costs, the company aims for revenue growth and improved margins through strategic execution.
The company's strengths lie in strong gross margins, record bookings in NGS, and efforts towards DNA data storage alliances, positioning for future growth and innovation.
Opportunities include continued customer expansion, Fast Gene market development, and revenue growth driven by NGS and SynBio performance, amidst a value-based pricing strategy.

Twist Bioscience Corp achieves $60.2M revenue in Q2 2023

Twist Bioscience Corp's Q2 2023 earnings call highlighted strong revenue growth, cost reduction efforts, and a focus on achieving profitability. The company is navigating challenges in the biopharma sector while leveraging strengths in technology and sales execution for future growth.

Twist Bioscience Corp reports record Q3 revenue, focuses on growth

Twist Bioscience Corp delivered a strong performance in Q3, with record revenue and strategic product launches driving growth across key segments.
While facing challenges in biopharma revenue and commercial execution, the company is focused on expansion, talent acquisition, and cost management to drive future growth.
With a clear focus on innovation, market expansion, and achieving profitability milestones, Twist Bioscience Corp is well-positioned for future success and market leadership.
The company's strengths in SynBio products, strategic market positioning, and stable funding outlook underscore its potential for sustained growth and value creation.

Twist Bioscience Corp reports robust revenue growth and eyes profitability

Twist Bioscience Corp's Q4 2023 earnings call highlighted strong revenue growth, operational efficiency, and a solid financial position.
The company faces challenges in managing expenses and achieving profitability but sees opportunities in revenue growth and market expansion.
By leveraging strengths in product launches, customer relationships, and revenue growth, Twist Bioscience aims for continued success and margin expansion in fiscal 2024.

Twist Bioscience Corp excels in Q1 2024, focuses on growth

Twist Bioscience Corp's Q1 2024 earnings call highlighted robust revenue growth, margin expansion, and strategic focus on operational efficiency. The company's emphasis on customer needs, premium pricing, and cost efficiency positions it well for future growth and profitability.

Twist Bioscience reports robust Q2 revenue growth and margin targets

Twist Bioscience Corp delivered strong revenue growth and aims for margin improvement, driven by successful product lines and strategic initiatives.
While facing challenges in managing expenses and achieving profitability, the company is well-positioned to leverage market opportunities and regulatory advantages.
With a focus on innovation, market expansion, and margin growth, Twist is poised for continued success and competitive growth in the biopharma sector.
Navigating operational challenges and seizing growth opportunities will be crucial for Twist Bioscience to achieve its financial targets and sustain market leadership.

Twist Bioscience Corp reports robust Q3 revenue growth and profitability outlook

Twist Bioscience Corp delivered strong revenue growth and operational performance in Q3 2024, driven by robust NGS and biopharma revenue streams.
While facing challenges in achieving profitability targets, the company's focus on margin improvement and capacity expansion positions it for future growth.
Guidance for fiscal 2024 indicates promising revenue growth, highlighting opportunities for sustained expansion and enhanced financial performance.

Twist Bioscience Corp reports record revenue and aims for profitability

Twist Bioscience Corp delivered strong financial performance, with record revenue and margin growth driven by key product segments and operational efficiencies.
The company's focus on achieving adjusted EBITDA profitability and cash flow positivity, along with robust fiscal 2025 guidance, signals a path towards sustainable growth.
While challenges like cost management and market competition persist, opportunities in market traction, revenue diversification, and innovation position the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Illumina

Western Digital

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--The DNA Data Storage Alliance, an organization of more than 25 leading companies formed by Twist Bioscience Corporation (NASDAQ: TWST), Illumina, Inc. (NASDAQ: ILMN) and Western Digital (NASDAQ: WDC) together with Microsoft Research, today announced its first white paper titled “Preserving our Digital Legacy: An Introduction to DNA Data Storage.” The white paper, which can be found on the newly launched DNA Data Storage Alliance website, www.dnastor

DNA Data Storage Alliance Publishes First White Paper, Launches Website

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has started shipping its synthetic RNA reference controls for the SARS-CoV-2 Kappa (B.1.617.1) variant strain. The company is also working on controls for the SARS-CoV-2 Delta (B.1.617.2) and B.1.617.3 variants. All three variants were first identified in India. “T

Twist Bioscience Begins Shipping of Synthetic RNA Controls for Kappa (B.1.617.1) SARS-CoV-2 Variants for Development of Accurate Tests

Pacific Biosciences of California

Incredible scientific advances could reward investors -- if they have the patience.

2 Top Biotech Picks to Buy and Hold for the Next 10 Years

CRISPR Therapeutics

Exact Sciences

Teladoc

They're well below peak levels set earlier this year. But they could be huge winners over the long run.

4 Unstoppable Healthcare Stocks to Buy on the Dip

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) today launched the Twist Library Preparation Enzymatic Fragmentation Kit 2.0, a robust all-in-one solution designed to maximize accuracy and efficiency in library construction and amplification when conducting next-generation sequencing (NGS). The kit is optimized for challenging NGS applications including liquid biopsy, somatic variant testing and genome-wide association studies. In addition, the kit exce

Twist Bioscience Launches Enzymatic Fragmentation Library Preparation Kit for High Uniformity, High-Yield Amplification, Streamlined Next Generation Sequencing Workflow for Targeted Applications

Female entrepreneurs are disrupting the traditionally male-dominated field of bioscience. One such disruptor is Dr. Emily Leproust, CEO and co-founder of Twist Bioscience (TWST), whose pioneering work on DNA-based applications and high-throughput DNA synthesis and sequencing is being used in everything from the fight against COVID-19 to brewing a better bottle of beer.

Twist Bioscience's Dr. Emily LeProust Disrupting the Future of Bioscience

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced its support of the Engineering Biology Research Consortium (EBRC) and its Statement of Ethics in Engineering Biology Research. A companion paper, titled “Guiding ethical principles in engineering biology research,” to contextualize the purpose and principles behind the Sta

Twist Bioscience Supports the Engineering Biology Research Consortium as it Publishes Statement of Ethics

What Are the Risks With Twist Bioscience?

Twist Bioscience Corporation (TWST) CEO Dr. Emily Leproust on Q2 2021 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2021 ended March 31, 2021. “The second quarter of our fiscal year delivered growth across all four areas of our business, with increasing revenue and very strong orders building momentum for the seco

Twist Bioscience Reports Second Quarter Fiscal 2021 Financial Results

ARK Genomic Revolution Multi-Sector ETF

Twist Bioscience brings to mind another genomic revolution pioneer.

Why Does Cathie Wood Like This Healthcare Stock So Much?

Investors will focus on the top-line and bottom-line numbers when Twist (TWST) reports fiscal second-quarter 2021 results.

Is a Beat in the Cards for Twist (TWS) This Earnings Season?

SOUTH SAN FRANCISCO, Calif. & FRANKFURT--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Vivlion GmbH, a company providing next-generation CRISPR gRNA libraries and screening services for the global R&D market, today announced a collaboration for the generation of gRNA libraries for CRISPR applications. CRISPR\Cas is a powerful functional genomics tool use

Twist Bioscience and Vivlion Partner to Generate gRNA Libraries for CRISPR Applications

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2021 second quarter ended March 31, 2021, following the close of market on Thursday, May 6, 2021. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time

Twist Bioscience to Report Fiscal 2021 Second Quarter Financial Results on Thursday, May 6, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has exercised its right of first refusal to expand the lease for its “Factory of the Future” manufacturing facility near Portland, Oregon. The expanded lease secures an additional approximately 100,000-square-foot facility within the same building as the approximat

Twist Bioscience to Expand Oregon Lease, Supporting Future Growth

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

And they all have one key thing in common.

4 Cathie Wood Stocks That Could Deliver Bigger Gains Than Tesla

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a partnership with Pure Biologics to accelerate the discovery of immuno-oncology antibody-based drugs. “Twist's unique technological approaches and abilities allow for the rapid generation of diverse synthetic libraries with novel and recent data-based randomization scheme

Pure Biologics Selects Twist Bioscience to Expand Phage Display Technology Capabilities

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will exercise its option to purchase all rights to a G-coupled protein receptor (GPCR) library and its proprietary Twist Antibody Optimization (TAO) software, both developed in collaboration with Distributed Bio. “We began working with Distributed Bio in 2016, before the exist

Twist Bioscience Exercises Option to Purchase Custom Designed Antibody Library and Optimization Software

SOUTH SAN FRANCISCO, Calif & BEIJING--(BUSINESS WIRE)--AcornMed Biotechnology Co., Ltd. (AcornMed), a precision medicine organization that specializes in the testing and analysis of solid and blood tumors, announced today that they will incorporate Twist Bioscience next generation sequencing (NGS) target enrichment and library preparation panels into AcornMed's portfolio of tests designed to provide insight into the genetic predisposition and treatment regimens for patients, providing a more ta

AcornMed Selects Twist Bioscience Technology to Power Next Generation Precision Medicine Tests

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, has signed an agreement enabling multiple academic laboratories at Stanford University to access Twist Bioscience's innovative antibody discovery and optimization services as well as its unique “Library of Libraries” for biologics discovery. Through Stanford's Innovative Medicines Acceler

Twist Bioscience to Provide Antibody Discovery, Optimization and Access to Library of Libraries for Drug Research to Stanford University Laboratories

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, is proud to be Certified™ by Great Place to Work®. The prestigious award is based entirely on what current employees say about their experience working at Twist Bioscience. Great Place to Work® is the global authority on workplace culture, employee experience and the leadership behaviors proven to de

Twist Bioscience Earns 2021 Great Place to Work Certification™

SOUTH SAN FRANCISCO, Calif. & LA JOLLA, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it signed a partnership agreement with Kyowa Kirin Pharmaceutical Research, Inc., a subsidiary of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company, to discover novel antibodies for therapeutic use against an

Twist Bioscience and Kyowa Kirin Partner for GPCR Antibody Discovery

Fate Therapeutics

These biotech companies are small, but they have tremendous growth prospects.

2 Under-the-Radar Stocks Cathie Wood Loves That Could Be Huge Winners

Shares of Twist Bioscience Corp. were down 1.6% in premarket trading on Wednesday after the company said its in-vitro diagnostic test that can detect SARS-CoV-2 RNA received emergency authorization in the U.S. Twist's test can identify the presence of the virus from a patient sample; it can also be used by Biotia Inc.'s software system to analyze the sequence and detect any genetic variants. So-called "variants of concern" have emerged over the last six months, including the B.1.1.7 variant out of the U.K., which is thought to be more infectious and makes up to 30% of all new U.S. cases, according to the Centers for Disease Control and Prevention.

Twist's COVID-19 test, which can detect variants, gets authorized

SOUTH SAN FRANCISCO, Calif. & NEW YORK--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Biotia, Inc., a company that uses proprietary analytical software for infectious disease diagnostics, today received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 Next-Generation Sequencing (NGS) Assay. The SARS-CoV-2

Twist Bioscience and Biotia Receive U.S. FDA Emergency Use Authorization for First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay

News for Twist Bioscience Corp Stock (TWST)